Skip to main content

Table 1 Characteristics of patients and tumors

From: Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

 

N = 56 (%)

Median Age (years, range)

68 (42–88)

Gender

 Male

29 (52)

 Female

27 (48)

ECOG Performance Status

 0

3 (5)

 1

41 (73)

 2

12 (21)

Primary tumor location

 Head

28 (50)

 Body

11 (20)

 Tail

12 (21)

 Body and tail

5 (9)

Stage at start of treatment

 III

2 (4)

 IV

54 (96)

Metastatic sites

 Liver

41 (73)

 Peritoneum

16 (29)

 Lung

15 (27)

 Distant lymph nodes

18 (32)

 Other

10 (18)

Number of metastatic sites

 1

29 (52)

 2

8 (14)

 3 or more

16 (29)

Prior lines of advanced disease therapy

 0

4 (7)

 1

20 (36)

 2

21 (38)

 3 or more

11 (20)